Edgewise reports positive Phase 1b results for EDG-5506 in Becker MD: biomarkers reduced 71-83%

Edgewise Therapeutics, Inc.

EDG-5506 well tolerated with no serious adverse events; dizziness was mild and transient.
CK reduced 71% and TNNI2 reduced 83% after two weeks, near healthy volunteer levels.
Plasma and muscle exposures exceeded pharmacologically active levels from preclinical models.
No effect on voluntary grip, shoulder, or hip strength; ARCH open-label study enrolling.
Management webcast today at 9 a.m. ET to discuss findings.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.